Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
23.18
-0.26 (-1.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Thera CS
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Russell 2000 Traders Place Bearish Bets Via IWM ETF
July 13, 2021
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM...
Via
Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
July 12, 2021
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...
Via
Benzinga
A Comprehensive Guide To Genomic ETFs
July 11, 2021
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...
Via
Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
July 11, 2021
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
Via
The Motley Fool
US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA
July 10, 2021
Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia.
Via
Talk Markets
Analyst Ratings For Intellia Therapeutics
June 29, 2021
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA
Via
Benzinga
Is It Too Late to Buy Intellia Therapeutics?
July 10, 2021
After skyrocketing 68% last week, will this stock keep running higher?
Via
The Motley Fool
Here's Why Regeneron Gained 11% Last Month
July 07, 2021
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.
Via
The Motley Fool
2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't
July 04, 2021
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.
Via
The Motley Fool
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
July 02, 2021
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.
Via
Investor's Business Daily
Topics
Initial Public Offering
Stocks
Exposures
Fossil Fuels
Securities Market
US Equities
Here's What Drove Gene Editing Stocks Higher This Week
July 02, 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Via
The Motley Fool
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
July 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...
Via
Benzinga
Exposures
Product Safety
5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now
July 01, 2021
Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.
Via
The Motley Fool
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
July 01, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...
Via
Benzinga
72 Biggest Movers From Yesterday
July 01, 2021
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
June 30, 2021
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...
Via
Benzinga
Why Intellia Therapeutics Was a Winner on Wednesday
June 30, 2021
The company is about to fatten its coffers significantly.
Via
The Motley Fool
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
June 30, 2021
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,...
Via
Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
June 30, 2021
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.
Via
InvestorPlace
Why Gene Editing Stocks Are Trading Higher Again Today
June 30, 2021
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 30, 2021
Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume...
Via
Benzinga
51 Stocks Moving In Wednesday's Mid-Day Session
June 30, 2021
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...
Via
Benzinga
Unusual Options Activity Insight: Intellia Therapeutics
June 30, 2021
Shares of Intellia Therapeutics (NASDAQ:NTLA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $183.36. Sentiment...
Via
Benzinga
Stocks That Hit 52-Week Highs On Wednesday
June 30, 2021
This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA...
Via
Benzinga
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
June 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share
June 30, 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close...
Via
Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
June 30, 2021
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Via
The Motley Fool
Exposures
COVID-19
58 Biggest Movers From Yesterday
June 30, 2021
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....
Via
Benzinga
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
June 29, 2021
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...
Via
Benzinga
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
June 29, 2021
Via
FinancialNewsMedia
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.